8-K current report · filed Nov 5, 2026

GYRE THERAPEUTICS, INC. (GYRE) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2GYRE overview

Short answer

GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Press release covers financial results for the three and nine months ended September 30, 2026.

GYRE THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers financial results for the three and nine months ended September 30, 2026
  • Investor-relevant figures and management commentary are contained in Exhibit 99.1
  • Results provide the latest update on Gyre’s operating performance and financial position

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation released November 5, 2026, signaling refreshed investor messaging
  • Exhibit 99.2 contains the substantive presentation, potentially including business, pipeline or strategy updates

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $32.9M, up 1%; ETUARY sales $31.4M offset lower Etorel and Contiva revenue under China procurement
  • Q3 net loss $2.5M, versus $1.9M income; basic EPS $(0.04), reflecting higher operating and other expenses
  • Nine-month net loss $35.3M, versus $4.6M income; revenue fell $6.5M to $86.5M after Astellas collaboration revenue ended
  • Cash and investments $98.8M, down 15% from December 31, 2025; liquidity supports pipeline execution but burn remains material
  • F351 NMPA decision expected by year-end 2026 or Q1 2027; full-year revenue guidance $100.5M to $111.0M affirmed

Item EX-99.2 · Exhibit EX-99.2

  • Corporate presentation frames China operations and ETUARY revenue as funding for a diversified U.S.-China degrader pipeline
  • ETUARY FY26 revenue guidance $100.5M-$111M, supporting capital-efficient research without dilution dependence
  • F351 Phase 3 fibrosis regression 52.85% versus placebo 29.84%, with NMPA decision expected by YE26/1Q27
  • F351 potential China launch in 1H27, adding a near-term growth catalyst to the commercial fibrosis portfolio
  • CG001419 Phase 1 completed, with Phase 2 cancer-induced bone pain study planned in the U.S. or China

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other GYRE THERAPEUTICS, INC. 8-K filings

Get the next GYRE 8-K as it lands

Follow GYRE for push alerts, or ask the research agent what this filing means.